相关实验视频
Updated: May 24, 2025
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
217
所有编程细胞死亡蛋白1抑制剂都是一样的吗?
Jochen H Lorch1, Stacey Stein2, Martin J Edelman3
1Department of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Frontiers in oncology
|March 3, 2025
概括
编程细胞死亡蛋白1 (PD-1) 抑制剂提供了新的癌症治疗方法. 需要进行对比试验,以确定toripalimab与其他PD-1抑制剂 (如pembrolizumab和nivolumab) 相比,是否有意义上的差异.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 编程细胞死亡蛋白1 (PD-1) 抑制剂是FDA批准的癌症疗法.
- 没有头对头的3期随机对照试验 (RCT) 存在来比较这些药物.
- 了解PD-1抑制剂之间的差异对于临床决策至关重要.
研究的目的:
- 审查比较PD-1抑制剂的临床前数据.
- 评估toripalimab与pembrolizumab和nivolumab的潜在差异化概况.
- 突出需要进行对比试验以确定临床差异.
主要方法:
- 对直接比较PD-1抑制剂的临床前研究的综述.
- 结合特征 (位置,方向) 和T细胞功能影响的分析.
- 对鼻癌和非小细胞肺癌的临床试验结果的审查.
主要成果:
- 临床前数据表明,托利帕利马布在PD-1相互作用和T细胞调节方面与潘布罗利祖马布和尼沃卢马布有着截然不同的特征.
- 托里帕利马布加化疗在患有晚期癌症的PD-L1表达较低或不表达的患者中显示出可比或更高的生存益处.
- 在特定癌症类型的整体存活期和无进展存活期观察到的好处.
结论:
- 临床前证据表明PD-1抑制剂之间的潜在差异.
- 托里帕利马布显示出有前途的疗效,特别是在某些患者子组.
- 进一步的对比RCT对于最终确定PD-1抑制剂之间临床上有意义的差异至关重要.
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:31The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K